Ligand validation:5VB2

PX4: 1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE

PX4 is a Ligand Of Interest in 5VB2 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5VB2_PX4_B_2306	22%	45%	0.213	0.907	1.11	1	1	2	0	0	57%	0.5652
5VB2_PX4_B_2304	19%	44%	0.247	0.898	1.04	1.11	2	1	0	0	67%	0.6739
5VB2_PX4_A_1303	15%	51%	0.265	0.907	1.14	0.78	2	1	2	0	57%	0.5652
5VB2_PX4_C_1304	12%	52%	0.266	0.866	1.12	0.76	2	1	0	0	59%	0.587
5VB2_PX4_C_1303	8%	32%	0.261	0.828	1.45	1.24	4	2	0	0	43%	0.4348
5VB2_PX4_A_1304	7%	39%	0.303	0.849	1.28	1.11	3	1	2	0	54%	0.5435
5VB2_PX4_D_2303	6%	32%	0.297	0.828	1.48	1.21	4	2	0	0	41%	0.413
5VB2_PX4_C_1305	5%	46%	0.395	0.841	1.12	0.98	4	2	0	0	78%	0.7826
5VB2_PX4_B_2305	4%	35%	0.32	0.799	1.39	1.19	5	2	0	0	48%	0.4783
5VB2_PX4_A_1305	4%	43%	0.391	0.821	1.18	1.05	4	2	0	0	72%	0.7174
5VB2_PX4_D_2305	3%	28%	0.321	0.762	1.42	1.49	4	3	0	0	46%	0.4565
5VB2_PX4_B_2303	2%	40%	0.435	0.796	1.28	1.06	4	2	0	0	61%	0.6087
5VB2_PX4_D_2304	2%	41%	0.496	0.81	1.3	1.02	4	2	0	0	59%	0.587
8DJ0_PX4_A_1301	65%	83%	0.148	0.949	0.31	0.46	-	-	2	0	100%	1
8DJ1_PX4_A_1301	54%	89%	0.18	0.954	0.28	0.36	-	-	1	0	96%	0.9565
8DIV_PX4_A_1302	50%	72%	0.182	0.934	0.4	0.69	-	3	1	0	100%	1
8DIZ_PX4_A_1302	50%	81%	0.167	0.941	0.28	0.53	-	-	1	0	87%	0.8696
6P6X_PX4_A_2001	45%	72%	0.193	0.932	0.51	0.58	-	-	3	0	96%	0.9565
6C1M_PX4_B_2306	43%	37%	0.188	0.948	1.28	1.21	3	3	0	0	80%	0.8043

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.